Last reviewed · How we verify
NORGESTOMET
Norgestomet, a marketed drug that binds to the progesterone receptor to mimic progesterone's effects, faces competition from several drugs targeting the same mechanism, including beclometasone dipropionate, darolutamide, eplerenone, fluticasone furoate, and prednisolone. A key strength of Norgestomet is its patent protection until 2028, providing a period of exclusivity before potential generic entry. The primary risk is the strong presence of off-patent competitors like eplerenone and prednisolone, which may limit market share and pricing power.
At a glance
| Generic name | NORGESTOMET |
|---|---|
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NORGESTOMET CI brief — competitive landscape report
- NORGESTOMET updates RSS · CI watch RSS